Knowing me, knowing you: Can a knowledge of risk factors for Alzheimer's disease prove useful in understanding the pathogenesis of Parkinson's disease?

Journal of Alzheimer's Disease

Volumn 25, Issue 3, 2011, Pages 395-415

  Sutherland, Greg T ^a   Siebert, Gerhard A ^b   Kril, Jillian J ^a   Mellick, George D ^b,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Alzheimer's disease; association studies; dementia; neuropathology; Parkinson's disease

Indexed keywords

APOLIPOPROTEIN E; PESTICIDE; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COGNITIVE DEFECT; DIFFUSE LEWY BODY DISEASE; EDUCATIONAL STATUS; FAMILY HISTORY; HEAD INJURY; HUMAN; NEUROPATHOLOGY; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE;

EID: 79960772040     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-110026     Document Type: Review

References (267)

1. Le Couteur DG, Muller M, Yang MC, Mellick GD, McLean AJ (2002) Age-environment and gene-environment interac-tionsinthe pathogenesisof Parkinson's disease.Rev Environ Health 17, 51-64. (Pubitemid 34984324)
2. Tol J, Roks G, Slooter AJ, van Duijn CM (1999) Genetic and environmental factors in Alzheimer's disease. Rev Neurol (Paris) 155 (Suppl 4), S10-S16.
3. Mellick GD, Silburn PA, Sutherland GT, Siebert GA (2010) Exploiting the potential of molecular profiling in Parkinson's disease: current practice and future probabilities. Expert Rev Mol Diagn 10, 1035-1050.
4. Lippa CF, Smith TW, Swearer JM (1994) Alzheimer's disease and Lewy body disease: a comparative clinicopatho-logical study. Ann Neurol 35, 81-88. (Pubitemid 24027610)
5. McKeith IG, Ince P, Jaros EB, Fairbairn A, Ballard C, Grace J, Morris CM, Perry RH (1998) What are the relations between Lewy body disease and AD?J Neural Transm Suppl 54, 107-116. (Pubitemid 28539347)
6. Strobel G (2009) The spectrum series: grappling with the overlap between Alzheimer's and Parkinson's diseases. 9th International Conference on Alzheimer's and Parkinson's Diseases, 11-15 March 2009, Prague, Czech Republic. J Alzheimers Dis 18, 625-640.
7. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, et al. (1990) Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40, 1529-1534. (Pubitemid 20351344)
8. Jellinger KA (1999) Post mortem studies in Parkinson's disease - is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 56, 1-29.
9. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in Parkinson's disease. Brain 132, 2947-2957.
10. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S4-S9. (Pubitemid 30390598)
11. Fratiglioni L, De Ronchi D, Aguero-Torres H (1999) Worldwide prevalence and incidence of dementia. Drugs Aging 15, 365-375. (Pubitemid 29527871)
12. Jorm AF, Dear KB, Burgess NM (2005) Projectionsoffuture numbers of dementia cases in Australia with and without prevention. Aust N Z J Psychiatry 39, 959-963. (Pubitemid 43904431)
13. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Willis RJ, Wallace RB (2007) Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 125-132. (Pubitemid 350191430)
14. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239-259.
15. NIA-Reagan Institute Working Group (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18, S1-S2.
16. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET (1999) Application of the National Institute on Aging (NIA) -Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 58, 1147-1155. (Pubitemid 29519838)
17. Kril JJ, Patel S, Harding AJ, Halliday GM (2002) Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neu-ropathol 103, 370-376. (Pubitemid 36097032)
18. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639.
19. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP (1995) Neocortical neurofibrillary tangles correlate with dementia severityin Alzheimer's disease. Arch Neurol 52, 81-88.
20. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
21. Mellick GD, Maraganore DM, Silburn PA (2005) Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neu-rosci Lett 375, 112-116.
22. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, Fratiglioni L, Lobo A, Martinez-Lage J, Trenkwalder C, Hofman A (2000) Prevalenceof Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseasesinthe Elderly Research Group. Neurology 54, S21-S23. (Pubitemid 30390601)
23. Weintraub D, Comella CL, Horn S (2008) Parkinson's disease - Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 14, S40-S48. (Pubitemid 351451787)
24. Hughes AJ (1997) Clinicopathological aspects of Parkinson's disease. Eur Neurol 38 (Suppl 2), 13-20. (Pubitemid 27453773)
25. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neuro-surg Psychiatry 55, 181-184.
26. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20, 415-455.
27. Cheng HC, Ulane CM, Burke RE (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67, 715-725.
28. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211. (Pubitemid 36007810)
29. Braak H, Muller CM, Rub U, Ackermann H, Bratzke H, de Vos RA, Del Tredici K (2006) Pathology associated with sporadic Parkinson's disease - where does it end? J Neural Transm Suppl 70, 89-97. (Pubitemid 44622184)
30. Harding AJ, Stimson E, Henderson JM, Halliday GM (2002) Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 125, 2431-2445. (Pubitemid 35303503)
31. Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z (2007) Alpha-synuclein pathologyinthe olfactory pathways of dementia patients. J Anat 211, 117-124. (Pubitemid 47034515)
32. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK (2008) Controversies over the staging of alpha-synuclein pathology in Parkinson's disease. Acta Neuropathol 116, 125-128.
33. Jellinger K, Mizuno H (2003) Parkinson's disease. In Neu-rodegeneration: The Molecular Pathology of Dementia and Movement Disorders, Dickson D, ed. ISN Neuropath Press, Basel, pp. 159-187.
34. Leverenz JB, Umar I, Wang Q, Montine TJ, McMillan PJ, Tsuang DW, Jin J, Pan C, Shin J, Zhu D, Zhang J (2007) Proteomic identification of novel proteins in cortical lewy bodies. Brain Pathol 17, 139-145. (Pubitemid 46466133)
35. Jellinger KA (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792, 730-740.
36. Young VG, Halliday GM, Kril JJ (2008) Neuropathologic correlates of white matter hyperintensities. Neurology 71, 804-811.
37. Ziegler DA, Piguet O, Salat DH, Prince K, Connally E, Corkin S (2010) Cognition in healthy aging is related to regional white matter integrity, but not cortical thickness. Neurobiol Aging 31, 1912-1926.
38. Double KL, Halliday GM, Kril JJ, Harasty JA, Cullen K, Brooks WS, Creasey H, Broe GA (1996) Topography of brain atrophy during normal aging and Alzheimer's disease. Neurobiol Aging 17, 513-521. (Pubitemid 26274249)
39. Piguet O, Double KL, Kril JJ, Harasty J, Macdonald V, McRitchie DA, Halliday GM (2009) White matter loss in healthy ageing: a postmortem analysis. Neurobiol Aging 30, 1288-1295.
40. Harding AJ, Halliday GM, Kril JJ (1998) Variation in hip-pocampal neuron number with age and brain volume. Cereb Cortex 8, 710-718. (Pubitemid 28550893)
41. Terry RD, De Teresa R, Hansen LA (1987) Neocortical cell counts in normal human adult aging. Ann Neurol 21, 530-539. (Pubitemid 17081187)
42. Pakkenberg B, Gundersen HJ (1997) Neocortical neuron number in humans: effect of sex and age. J Comp Neurol 384, 312-320. (Pubitemid 27282046)
43. Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw JJ, Agid Y, Hirsch EC (2000) Preservation of midbrain catecholamin-ergic neurons in very old human subjects. Brain 123 (Pt 2), 366-373. (Pubitemid 30055159)
44. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5), 2283-2301.
45. Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18, 351-357. (Pubitemid 27435070)
46. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR (1999) Alzheimer neuropathologic alterations in aged cog-nitively normal subjects. J Neuropathol Exp Neurol 58, 376-388. (Pubitemid 29187900)
47. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (2001) Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357, 169-175.
48. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC (2003) Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62, 1087-1095. (Pubitemid 37413820)
49. Pikkarainen M, Kauppinen T, Alafuzoff I (2009) Hyper-phosphorylated tau in the occipital cortex in aged nondemented subjects. J Neuropathol Exp Neurol 68, 653-660.
50. McKee AC, Au R, Cabral HJ, Kowall NW, Seshadri S, Kubilus CA, Drake J, Wolf PA (2006) Visual association pathology in preclinical Alzheimer disease. J Neuropathol Exp Neurol 65, 621-630. (Pubitemid 44288946)
51. Price JL, McKeel DW Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dick-son DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Hig-don R, Kukull W, Morris JC (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30, 1026-1036.
52. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR (2000) "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 55, 370-376. (Pubitemid 30654797)
53. Troncoso JC, Martin LJ, Dal Forno G, Kawas CH (1996) Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 17, 365-371. (Pubitemid 26200413)
54. Jellinger KA (2004) Lewy body-related alpha-synucleino-pathy in the aged human brain. J Neural Transm 111, 1219-1235. (Pubitemid 39468387)
55. Markesbery WR, Jicha GA, Liu H, Schmitt FA (2009) Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol 68, 816-822.
56. Adler CH, Connor DJ, Hentz JG, Sabbagh MN, Caviness JN, Shill HA, Noble B, Beach TG (2010) Incidental Lewy body disease: clinical comparison to a control cohort. Mov Disord 25, 642-646.
57. Uryu K, Giasson BI, Longhi L, Martinez D, Murray I, Conte V, Nakamura M, Saatman K, Talbot K, Horiguchi T, McIn-tosh T, Lee VM, Trojanowski JQ (2003) Age-dependent synuclein pathology following traumatic brain injury in mice. Exp Neurol 184, 214-224. (Pubitemid 37444032)
58. Dickson DW, Fujishiro H, Delle Donne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neu-ropathol 115, 437-444.
59. Frigerio R, Fujishiro H, Ahn TB, Josephs KA, Maraganore DM, Delledonne A, Parisi JE, Klos KJ, Boeve BF, Dickson DW, Ahlskog JE (2009) Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging doi:10.1016/ j.neurobiolaging.2009.05.019
60. Kril JJ (2009) Alzheimer disease: Alzheimer disease neu-ropathology in the oldest old. Nat Rev Neurol 5, 411-412.
61. Haroutunian V, Schnaider-Beeri M, Schmeidler J, Wysocki M, Purohit DP, Perl DP, Libow LS, Lesser GT, Maroukian M, Grossman HT (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65, 1211-1217.
62. Polvikoski T, Sulkava R, Rastas S, Sutela A, Niinisto L, Notkola IL, Verkkoniemi A, Viramo P, Juva K, Haltia M (2006) Incidence of dementia in very elderly individuals: a clinical, neuropathological and molecular genetic study. Neuroepidemiology 26, 76-82. (Pubitemid 43201302)
63. Prohovnik I, Perl DP, Davis KL, Libow L, Lesser G, Haroutunian V (2006) Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease. Neurology 66, 49-55. (Pubitemid 43739591)
64. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C (2009) Age, neuropathology, and dementia. N Engl J Med 360, 2302-2309.
65. Jellinger KA, Attems J (2010) Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol 119, 421-433.
66. Laukka EJ, Fratiglioni L, Backman L (2010) The influence of vascular disease on cognitive performance in the preclini-cal and early phases of Alzheimer's disease. Dement Geriatr Cogn Disord 29, 498-503.
67. Strozyk D, Dickson DW, Lipton RB, Katz M, Derby CA, Lee S, Wang C, Verghese J (2010) Contribution of vascular pathology to the clinical expression of dementia. Neurobiol Aging 31, 1710-1720.
68. Ding ZT, Wang Y, Jiang YP, Hashizume Y, Yoshida M, Mimuro M, Inagaki T, Iwase T (2006) Characteristics of alpha-synucleinopathy in centenarians. Acta Neuropathol (Berl) 111, 450-458.
69. Liao YC, Liu RS, Teng EL, Lee YC, Wang PN, Lin KN, Chung CP, Liu HC (2005) Cognitive reserve: a SPECT study of 132 Alzheimer's disease patients with an education range of 0-19 years. Dement Geriatr Cogn Disord 20, 8-14. (Pubitemid 40981172)
70. Frigerio R, Fujishiro H, Maraganore DM, Klos KJ, Delle-Donne A, Heckman MG, Crook JE, Josephs KA, Parisi JE, Boeve BF, Dickson DW, Ahlskog JE (2009) Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease. Arch Neurol 66, 1114-1119.
71. Hamilton RL (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10, 378-384. (Pubitemid 30431290)
72. Jellinger KA (2003) Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution - a pilot study. Acta Neuropathol 106, 191-201. (Pubitemid 37021251)
73. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA (2009) The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18, 691-701.
74. Uchikado H, Lin WL, De Lucia MW, Dickson DW (2006) Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65, 685-697. (Pubitemid 44297259)
75. Braak H, Braak E, Yilmazer D, Bohl J (1996) Functional anatomy of human hippocampal formation and related structures. J Child Neurol 11, 265-275.
76. Jellinger KA, Seppi K, Wenning GK, Poewe W (2002) Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109, 329-339. (Pubitemid 34251637)
77. Mann DM, Jones D (1990) Deposition of amyloid (A4) protein within the brains of persons with dementing disorders other than Alzheimer's disease and Down's syndrome. Neurosci Lett 109, 68-75. (Pubitemid 20036474)
78. Papapetropoulos S, Lieberman A, Gonzalez J, Mash DC (2005) Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Acta Neurol Scand 111, 353-359. (Pubitemid 40705304)
79. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aars-land D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872. (Pubitemid 43970103)
80. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) : report of the consortium on DLB international workshop. Neurology 47, 1113-1124. (Pubitemid 26374873)
81. Zaccai J, McCracken C, Brayne C (2005) A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34, 561-566. (Pubitemid 41699997)
82. McKeith I (2007) Dementia with Lewy bodies and Parkinson's disease with dementia: where two worlds collide. Pract Neurol 7, 374-382. (Pubitemid 350237713)
83. Halliday G, Hely M, Reid W, Morris J (2008) The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 115, 409-415.
84. Halliday GM, McCann H (2010) The progression of pathol-ogyin Parkinson's disease.Ann NY Acad Sci1184, 188-195.
85. Dodel R, Csoti I, Ebersbach G, Fuchs G, Hahne M, Kuhn W, Oechsner M, Jost W, Reichmann H, Schulz JB (2008) Lewy body dementia and Parkinson'sdisease with dementia. J Neurol 255 (Suppl 5), 39-47.
86. Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 20, 1255-1263. (Pubitemid 41645899)
87. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter studyof Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23, 837-844.
88. Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, Kukull WA, Leverenz JB, Cherrier MM (2005) Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 64, 2069-2073. (Pubitemid 40880995)
89. Aarsland D, Ballard C, Larsen JP, McKeith I (2001) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 16, 528-536. (Pubitemid 32492388)
90. Kramer ML, Schulz-Schaeffer WJ (2007) Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neu-rodegeneration in dementia with Lewy bodies. J Neurosci 27, 1405-1410.
91. Siebert H, Kahle PJ, Kramer ML, Isik T, Schluter OM, Schulz-Schaeffer WJ, Bruck W (2010) Over-expression of alpha-synuclein in the nervous system enhances axonal degeneration after peripheral nerve lesion in a transgenic mouse strain. J Neurochem 114, 1007-1018.
92. Deramecourt V, Bombois S, Maurage CA, Ghestem A, Drobecq H, Vanmechelen E, Lebert F, Pasquier F, Dela-courte A (2006) Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 65, 278-288.
93. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, Waters C, Jimison P, Shepherd E, Sevush S, Graff-Radford N, Newland D, Todd M, Miller B, Gold M, Heilman K, Doty L, Goodman I, Robinson B, Pearl G, Dickson D, Duara R (2002) Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotem-poral dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 16, 203-212. (Pubitemid 35434796)
94. Jellinger KA (2011) Interaction between alpha-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 227, 13-18.
95. Jellinger KA (2010) Basic mechanisms of neurodegenera-tion: a critical update. J Cell Mol Med 14, 457-487.
96. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300, 636-640. (Pubitemid 36520587)
97. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the Cam Pa IGN cohort. Brain 132 (Pt 11), 2958-2969.
98. Mikolaenko I, Pletnikova O, Kawas CH, O'Brien R, Resnick SM, Crain B, Troncoso JC (2005) Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol 64, 156-162. (Pubitemid 40349314)
99. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC (2005) Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26, 1183-1192. (Pubitemid 40726011)
100. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, La Ferla FM (2010) Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 30, 7281-7289.
101. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the Alz Gene database. Nat Genet 39, 17-23. (Pubitemid 46026496)
102. Lill CM, Bagade S, McQueen, Bagade S, Kavvoura F, Schjeide BMM, Allen NC, Tanzi R, Khoury MJ, Ioannidis JPA, Bertram L (2009) The PDGene Database. Alzheimer Research Forum, http://www.pdgene.org/, Accessed 08/10/09.
103. Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM (2001) Incidence of dementia: does gender make a difference? Neurobiol Aging 22, 575-580. (Pubitemid 32607742)
104. Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, Shen Y, Li R (2005) Brain estrogen defi-ciencyaccelerates Abeta plaque formationinan Alzheimer's disease animal model. Proc Natl Acad Sci U S A 102, 19198-19203. (Pubitemid 43049589)
105. Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA (2005) Sex differences inthe clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry 62, 685-691. (Pubitemid 40973444)
106. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J (2004) Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 75, 637-639. (Pubitemid 38406668)
107. Fujimi K, Sasaki K, Noda K, Wakisaka Y, Tanizaki Y, Mat-sui Y, Sekita A, Iida M, Kiyohara Y, Kanba S, Iwaki T (2008) Clinicopathological outline of dementia with Lewy bodies applying the revised criteria: the Hisayama Study. Brain Pathol 18, 317-325. (Pubitemid 351782854)
108. Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008) Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD).J Neurol255, 255-264.
109. Borroni B, Alberici A, Agosti C, Premi E, Padovani A (2008) Education playsadifferent role in Frontotemporal Dementia and Alzheimer's disease. Int J Geriatr Psychiatry 23, 796-800.
110. Kraszpulski M, Soininen H, Helisalmi S, Alafuzoff I (2001) The load and distribution of beta-amyloid in brain tissue of patients with Alzheimer's disease. Acta Neurol Scand 103, 88-92. (Pubitemid 32113101)
111. Johnson JK, McCleary R, Oshita MH, Cotman CW (1998) Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles. Brain Res 798, 18-24. (Pubitemid 28342016)
112. van Helmond Z, Miners JS, Kehoe PG, Love S (2010) Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol 20, 468-480.
113. Callahan MJ, Lipinski WJ, Bian F, Durham RA, Pack A, Walker LC (2001) Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol 158, 1173-1177. (Pubitemid 32221809)
114. Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, La Ferla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y (2008) Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res 1216, 92-103.
115. Caamano-Isorna F, Corral M, Montes-Martinez A, Tak-kouche B (2006) Education and dementia: a meta-analytic study. Neuroepidemiology 26, 226-232. (Pubitemid 43876726)
116. Perneczky R, Drzezga A, Diehl-Schmid J, Schmid G, Wohlschlager A, Kars S, Grimmer T, Wagenpfeil S, Monsch A, Kurz A (2006) Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose-positron emission tomography. J Neurol Neurosurg Psychiatry 77, 1060-1063. (Pubitemid 44338530)
117. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R (1994) Influence of education and occupation on the incidence of Alzheimer's disease. JAMA 271, 1004-1010. (Pubitemid 24099921)
118. Frigerio R, Elbaz A, Sanft KR, Peterson BJ, Bower JH, Ahlskog JE, Grossardt BR, de Andrade M, Maraganore DM, Rocca WA (2005) Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology 65, 1575-1583. (Pubitemid 41689471)
119. Cohen OS, Vakil E, Tanne D, Nitsan Z, Schwartz R, Hassin-Baer S (2007) Educational level as a modulator of cognitive performance and neuropsychyatric features in Parkinson disease. Cogn Behav Neurol 20, 68-72. (Pubitemid 46673714)
120. Glatt SL, Hubble JP, Lyons K, Paolo A, Troster AI, Has-sanein RE, Koller WC (1996) Risk factors for dementia in Parkinson's disease: effectofeducation. Neuroepidemiology 15, 20-25. (Pubitemid 26019107)
121. Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K (2002) Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study. Mov Disord 17, 250-257. (Pubitemid 36041293)
122. Louis ED, Tang MX, Mayeux R (2004) Parkinsonian signs in older people in a community-based study: risk of incident dementia. Arch Neurol 61, 1273-1276. (Pubitemid 39062684)
123. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J (2006) What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain 129, 729-735. (Pubitemid 43278234)
124. Guo Z, Cupples LA, Kurz A, Auerbach SH, Volicer L, Chui H, Green RC, Sadovnick AD, Duara R, De Carli C, Johnson K, Go RC, Growdon JH, Haines JL, Kukull WA, Farrer LA (2000) Head injury and the risk of AD in the MIRAGE study. Neurology 54, 1316-1323. (Pubitemid 30174053)
125. Starkstein SE, Jorge R (2005) Dementia after traumatic brain injury. Int Psychogeriatr 17 (Suppl 1), S93-S107. (Pubitemid 44561758)
126. Bower JH, Maraganore DM, Peterson BJ, McDonnell SK, Ahlskog JE, Rocca WA (2003) Head trauma preceding PD: a case-control study. Neurology 60, 1610-1615. (Pubitemid 36618086)
127. Rosso SM, Landweer EJ, Houterman M, Donker Kaat L, van Duijn CM, van Swieten JC (2003) Medical and environmental risk factors for sporadic frontotemporal dementia: a retrospective case-control study. J Neurol Neurosurg Psychiatry 74, 1574-1576.
128. Zemlan FP, Jauch EC, Mulchahey JJ, Gabbita SP, Rosenberg WS, Speciale SG, Zuccarello M (2002) C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinicaloutcome. Brain Res 947, 131-139. (Pubitemid 34876523)
129. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT (2010) Caspase activation precedes and leads to tangles. Nature 464, 1201-1204.
130. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, La Pointe N, Miller R, Berry RW, Binder LI, Cryns VL (2003) Cas-pase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A 100, 10032-10037. (Pubitemid 37087063)
131. Kim W, Lee S, Hall GF (2010) Secretion of human tau fragments resembling CSF-tau in Alzheimer's disease is modulated by the presence of the exon 2 insert. FEBS Lett 584, 3085-3088.
132. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J (2010) Dendritic function of Tau mediates amyloid-beta toxic-ity in Alzheimer's disease mouse models. Cell 142, 387-397.
133. Gentleman SM, Nash MJ, Sweeting CJ, Graham DI, Roberts GW (1993) Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci Lett 160, 139-144. (Pubitemid 23294725)
134. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI (1994) Beta amyloid protein depositioninthe brain after severe head injury: implications for the pathogen-esis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 57, 419-425.
135. Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, Hyman BT (1999) Alpha-synuclein immunoreactivity is present in axonal swellings in neuro-axonal dystrophy and acute traumatic brain injury. J Neu-ropathol Exp Neurol 58, 1263-1268.
136. Uryu K, Chen XH, Martinez D, Browne KD, Johnson VE, Graham DI, Lee VM, Trojanowski JQ, Smith DH (2007) Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Exp Neu-rol 208, 185-192. (Pubitemid 350101496)
137. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L (1999) The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 282, 40-46. (Pubitemid 29318931)
138. Helzner EP, Luchsinger JA, Scarmeas N, Cosentino S, Brickman AM, Glymour MM, Stern Y (2009) Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 66, 343-348.
139. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetyl-choline. J Alzheimers Dis 8, 247-268.
140. Hong M, Lee VM (1997) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272, 19547-19553. (Pubitemid 27337756)
141. Driver JA, Smith A, Buring JE, Gaziano JM, Kurth T, Logroscino G (2008) Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 31, 2003-2005.
142. Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP (2005) The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 112, 386-390. (Pubitemid 41695718)
143. Scigliano G, Musicco M, Soliveri P, Piccolo I, Ronchetti G, Girotti F (2006) Reduced risk factors for vascular disorders in Parkinson disease patients: a case-control study. Stroke 37, 1184-1188. (Pubitemid 43731859)
144. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR (2008) Diabetes in patients with idiopathic Parkinson's disease. Diabetes Care 31, 1808-1812.
145. Scigliano G, Ronchetti G, Girotti F, Musicco M (2009) Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson disease. Parkinsonism Relat Disord 15, 138-143.
146. Ke YD, Delerue F, Gladbach A, Gotz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One 4, e7917.
147. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52, 276-284. (Pubitemid 35001493)
148. Quik M (2004) Smoking, nicotine and Parkinson's disease. Trends Neurosci 27, 561-568. (Pubitemid 39149826)
149. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strickland D, Van Den Eeden SK, Gorell J (2007) Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64, 990-997. (Pubitemid 47047999)
150. Sugita M, Izuno T, Tatemichi M, Otahara Y (2001) Meta-analysis for epidemiologic studies on the relationship between smoking and Parkinson's disease. J Epidemiol 11, 87-94.
151. Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A (2007) Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 68, 764-768. (Pubitemid 46667902)
152. Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, Blair A (2010) Smoking duration, intensity, and risk of Parkinson disease. Neurology 74, 878-884.
153. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, Schaid DJ, Rocca WA (2000) Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology 55, 1350-1358.
154. Mellick GD, Gartner CE, Silburn PA, Battistutta D (2006) Passive smoking and Parkinson disease. Neurology 67, 179-180. (Pubitemid 44305495)
155. O'Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, Ascherio A (2005) Smokeless tobacco use and the risk of Parkinson's disease mortality. Mov Disord 20, 1383-1384. (Pubitemid 41645921)
156. Deng Y, Newman B, Dunne MP, Silburn PA, Mellick GD (2004) Case-only study of interactions between genetic polymorphisms of GSTM1, P1, T1 and Z1 and smoking in Parkinson's disease. Neurosci Lett 366, 326-331. (Pubitemid 39024291)
157. De Palma G, Dick FD, Calzetti S, Scott NW, Prescott GJ, Osborne A, Haites N, Mozzoni P, Negrotti A, Scaglioni A, Mutti A (2010) A case-control study of Parkinson's disease and tobacco use: gene-tobacco interactions. Mov Disord 25, 912-919.
158. McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Hig-gins DS, Griffith A, Roberts JW, Leis BC, Montimurro JS, Zabetian CP, Payami H (2008) Exploring gene-environment interactions in Parkinson's disease. Hum Genet 123, 257-265.
159. Gatto NM, Rhodes SL, Manthripragada AD, Bronstein J, Cockburn M, Farrer M, Ritz B (2010) alpha-Synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease. Neuroepidemiology 35, 191-195.
160. Saad M, Lesage S, Saint-Pierre A, Corvol JC, Zelenika D, Lambert JC, Vidailhet M, Mellick GD, Lohmann E, Durif F, Pollak P, Damier P, Tison F, Silburn PA, Tzourio C, Forlani S, Loriot MA, Giroud M, Helmer C, Portet F, Amouyel P, Lathrop M, Elbaz A, Durr A, Martinez M, Brice A (2011) Genome-wide association study confirms BST1 and suggests a locus on 12q24 as risk loci for Parkinson's disease in the European population. Hum Mol Genet 20, 615-627.
161. Anstey KJ, von Sanden C, Salim A, O'Kearney R (2007) Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 166, 367-378. (Pubitemid 47216800)
162. Cataldo JK, Prochaska JJ, Glantz SA (2009) Cigarette smoking is a risk factor for alzheimer's disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 19, 465-480.
163. Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, van Duijn CM, Breteler MM (1998) Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 351, 1840-1843. (Pubitemid 28279707)
164. Reitz C, den Heijer T, van Duijn C, Hofman A, Breteler MM (2007) Relation between smoking and risk of dementia and Alzheimer disease: the Rotterdam Study. Neurology 69, 998-1005. (Pubitemid 47366053)
165. Tsuang D, Larson EB, Li G, Shofer JB, Montine KS, Thompson ML, Sonnen JA, Crane PK, Leverenz JB, Montine TJ (2010) Association between lifetime cigarette smoking and lewy body accumulation. Brain Pathol 20, 412-418.
166. Kivipelto M, Rovio S, Ngandu T, Kareholt I, Eskelinen M, Winblad B, Hachinski V, Cedazo-Minguez A, Soininen H, Tuomilehto J, Nissinen A (2008) Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 12, 2762-2771.
167. Rusanen M, Rovio S, Ngandu T, Nissinen A, Tuomile-hto J, Soininen H, Kivipelto M (2010) Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer's disease: a population-based cardiovascular risk factors, aging and dementia study. Dement Geriatr Cogn Disord 30, 277-284.
168. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J (2007) Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298, 2654-2664. (Pubitemid 350254957)
169. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ (2008) Enhanced risk for Alzheimer disease in persons with type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 65, 89-93.
170. Sabbagh MN, Tyas SL, Emery SC, Hansen LA, Alford MF, Reid RT, Tiraboschi P, Thal LJ (2005) Smoking affects the phenotype of Alzheimer disease. Neurology 64, 1301-1303.
171. Barbeau A, Roy M, Cloutier T, Plasse L, Paris S (1987) Environmental and genetic factors in the etiology of Parkinson's disease. In Parkinson's Disease. Advances in Neurology. Yahr MD, Bergmann KJ, eds. Raven Press, New York, pp. 299-306.
172. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1, 249-254. (Pubitemid 10123385)
173. Langston JW, Ballard PA Jr (1983) Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1, 2, 5, 6-tetra-hydropyridine. N Engl J Med 309, 310. (Pubitemid 13074924)
174. Langston JW, Irwin I, Langston EB, Forno LS (1984) 1-Methyl-4- phenylpyridinium ion (MPP+) : identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett 48, 87-92. (Pubitemid 14084283)
175. Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE (1987) MPTP, MPP+ and mitochondrial function. Life Sci 40, 721-729.
176. Richardson JR, Quan Y, Sherer TB, Greenamyre JT, Miller GW (2005) Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol Sci 88, 193-201. (Pubitemid 41548761)
177. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS (2001) Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res 86, 122-127. (Pubitemid 32656305)
178. Mellick GD (2006) CYP450, genetics and Parkinson's disease: gene×environment interactions hold the key.J Neural Transm Suppl 70, 159-165. (Pubitemid 44622194)
179. Choi WS, Kruse SE, Palmiter RD, Xia Z (2008) Mitochon-drial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A 105, 15136-15141.
180. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E, Czech C, Gotz J, Eckert A (2009) Amyloid-beta and tau syn-ergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A 106, 20057-20062.
181. Hardy J (2006) No definitive evidence for a role for the environment in the etiology of Parkinson's disease. Mov Disord 21, 1790-1791. (Pubitemid 44742228)
182. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Paisan-Ruiz C, Lichtner P, Scholz SW, Hernandez DG, Kruger R, Federoff M, Klein C, Goate A, Perlmut-ter J, Bonin M, Nalls MA, Illig T, Gieger C, Houlden H, Steffens M, Okun MS, Racette BA, Cookson MR, Foote KD, Fernandez HH, Traynor BJ, Schreiber S, Arepalli S, Zonozi R, Gwinn K, van der Brug M, Lopez G, Chanock SJ, Schatzkin A, Park Y, Hollenbeck A, Gao J, Huang X, Wood NW, Lorenz D, Deuschl G, Chen H, Riess O, Hardy JA, Singleton AB, Gasser T (2009) Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 41, 1308-1312.
183. Rosen AR, Steenland NK, Hanfelt J, Factor SA, Lah JJ, Levey AI (2007) Evidence of shared risk for Alzheimer's disease and Parkinson's disease using family history. Neu-rogenetics 8, 263-270. (Pubitemid 47624447)
184. Rocca WA, Bower JH, Ahlskog JE, Elbaz A, Grossardt BR, McDonnell SK, Schaid DJ, Maraganore DM (2007) Risk of cognitive impairment or dementia in relatives of patients with Parkinson disease. Arch Neurol 64, 1458-1464. (Pubitemid 47572669)
185. Kurz MW, Larsen JP, Kvaloy JT, Aarsland D (2006) Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study. Mov Disord 21, 2170-2174. (Pubitemid 46140431)
186. Levy G, Louis ED, Mejia-Santana H, Cote L, Andrews H, Harris J, Waters C, Ford B, Frucht S, Fahn S, Ottman R, Marder K (2004) Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol 61, 1033-1039. (Pubitemid 38915944)
187. Papapetropoulos S, Lieberman A, Gonzalez J, Singer C, Laufer DZ, Mash DC (2006) Family history of dementia: dementia with lewy bodies and dementia in Parkinson's disease. J Neuropsychiatry Clin Neurosci 18, 113-116. (Pubitemid 43277265)
188. Brouwers N, Sleegers K, Van Broeckhoven C (2008) Molecular genetics of Alzheimer's disease: an update. Ann Med 40, 562-583.
189. Lesage S, Brice A (2009) Parkinson's disease: from mono-genic formstogeneticsusceptibility factors.Hum Mol Genet 18, R48-R59.
190. Clark LN, Kartsaklis LA, Wolf Gilbert R, Dorado B, Ross BM, Kisselev S, Verbitsky M, Mejia-Santana H, Cote LJ, Andrews H, Vonsattel JP, Fahn S, Mayeux R, Honig LS, Marder K (2009) Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol 66, 578-583.
191. Sutherland GT, Halliday GM, Silburn PA, Mastaglia FL, Rowe DB, Boyle RS, O'Sullivan JD, Ly T, Wilton SD, Mellick GD (2009) Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? Mov Disord 24, 833-838.
192. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T (2009) Genome-wide association study identifies common variants at four lociasgenetic risk factors for Parkinson's disease.Nat Genet 41, 1303-1307.
193. Edwards TL, Scott WK, Almonte C, Burt A, Powell EH, Beecham GW, Wang L, Zuchner S, Konidari I, Wang G, Singer C, Nahab F, Scott B, Stajich JM, Pericak-Vance M, Haines J, Vance JM, Martin ER (2010) Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 74, 97-109.
194. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. (Pubitemid 23275809)
195. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein Eto synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A 90, 8098-8102. (Pubitemid 23260862)
196. Ashford JW (2004) APOE genotype effects on Alzheimer's disease onset and epidemiology. J Mol Neurosci 23, 157-165. (Pubitemid 41389382)
197. Abraham R, Moskvina V, Sims R, Hollingworth P, Morgan A, Georgieva L, Dowzell K, Cichon S, Hillmer AM, O'Donovan MC, Williams J, Owen MJ, Kirov G (2008) A genome-wide association study for late-onset Alzheimer's disease using DNA pooling. BMC Med Genomics 1, 44.
198. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL, Pericak-Vance MA (2009) Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 84, 35-43.
199. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE (2008) Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 83, 623-632.
200. Carrasquillo MM, Zou F, Pankratz VS, Wilcox SL, Ma L, Walker LP, Younkin SG, Younkin CS, Younkin LH, Bisceglio GD, Ertekin-Taner N, Crook JE, Dickson DW, Petersen RC, Graff-Radford NR, Younkin SG (2009) Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat Genet 41, 192-198.
201. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 68, 613-618. (Pubitemid 46663046)
202. Feulner TM, Laws SM, Friedrich P, Wagenpfeil S, Wurst SH, Riehle C, Kuhn KA, Krawczak M, Schreiber S, Nikolaus S, Forstl H, Kurz A, Riemenschneider M (2010) Examination of the current top candidate genes for AD in a genome-wide association study. Mol Psychiatry 15, 756-766.
203. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hos-ford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65, 45-53.
204. Webster JA, Myers AJ, Pearson JV, Craig DW, Hu-Lince D, Coon KD, Zismann VL, Beach T, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Huentelman MJ, Joshipura K, Walker D, Heward CB, Ravid R, Rogers J, Papassotiropoulos A, Hardy J, Reiman EM, Stephan DA (2008) Sorl1as an Alzheimer's disease predisposition gene? Neurodegener Dis 5, 60-64.
205. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschlager A, Riemen-schneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487-1494.
206. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haa-pasalo H, Karhunen PJ (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65, 650-657.
207. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsada-nian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 97, 2892-2897. (Pubitemid 30159268)
208. Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T (2006) Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A 103, 18787-18792. (Pubitemid 44913488)
209. Verpillat P, Camuzat A, Hannequin D, Thomas-Anterion C, Puel M, Belliard S, Dubois B, Didic M, Lacomblez L, More-aud O, Golfier V, Campion D, Brice A, Clerget-Darpoux F (2002) Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis. Eur J Hum Genet 10, 399-405.
210. Feher A, Juhasz A, Rimanoczy A, Kalman J, Janka Z (2009) Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. Alzheimer Dis Assoc Disord 23, 224-228.
211. Nervi A, Reitz C, Tang MX, Santana V, Piriz A, Reyes-Dumeyer D, Lantigua R, Medrano M, Jimenez-Velazquez IZ, Lee JH, Mayeux R (2008) Comparison of clinical manifestations in Alzheimer disease and dementia with Lewy bodies. Arch Neurol 65, 1634-1639.
212. Singleton AB, Wharton A, O'Brien KK, Walker MP, McK-eith IG, Ballard CG, O'Brien J, Perry RH, Ince PG, Edwardson JA, Morris CM (2002) Clinical and neuropatho-logical correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dement Geriatr Cogn Disord 14, 167-175. (Pubitemid 36151483)
213. Parsian A, Racette B, Goldsmith LJ, Perlmutter JS (2002) Parkinson's disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 79, 458-461. (Pubitemid 34211955)
214. Huang X, Chen P, Kaufer DI, Troster AI, Poole C (2006) Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol 63, 189-193. (Pubitemid 43261729)
215. Williams-Gray CH, Goris A, Saiki M, Foltynie T, Comp-ston DA, Sawcer SJ, Barker RA (2009) Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 256, 493-498.
216. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA (2008) Imaging amyloid deposition in Lewy body diseases. Neurology 71, 903-910.
217. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67, 308-316.
218. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256, 184-185.
219. Hutton M (2000) Molecular genetics of chromosome 17 tauopathies. Ann N Y Acad Sci 920, 63-73. (Pubitemid 32056553)
220. Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, Barnard J, Baker A, Jonasdottir A, Inga-son A, Gudnadottir VG, Desnica N, Hicks A, Gylfason A, Gudbjartsson DF, Jonsdottir GM, Sainz J, Agnarsson K, Bir-gisdottir B, Ghosh S, Olafsdottir A, Cazier JB, Kristjansson K, Frigge ML, Thorgeirsson TE, Gulcher JR, Kong A, Ste-fansson K (2005) A common inversion under selection in Europeans. Nat Genet 37, 129-137.
221. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, Hardy J, Lynch T, Bigio E, Hutton M (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8, 711-715. (Pubitemid 29139987)
222. Duda JE, Giasson BI, Mabon ME, Miller DC, Golbe LI, Lee VM, Trojanowski JQ (2002) Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (Berl) 104, 7-11. (Pubitemid 36075353)
223. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607. (Pubitemid 39531225)
224. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, Ban M, Spillantini MG, Compston A, Burn DJ, Chinnery PF, Barker RA, Sawcer SJ (2007) Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 62, 145-153. (Pubitemid 47546500)
225. Verpillat P, Camuzat A, Hannequin D, Thomas-Anterion C, Puel M, Belliard S, Dubois B, Didic M, Michel BF, Lacomblez L, Moreaud O, Sellal F, Golfier V, Campion D, Clerget-Darpoux F, Brice A (2002) Association between the extended tau haplotype and frontotemporal dementia. Arch Neurol 59, 935-939. (Pubitemid 34640753)
226. Kwok JB, Teber ET, Loy C, Hallupp M, Nicholson G, Mel-lick GD, Buchanan DD, Silburn PA, Schofield PR (2004) Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 55, 329-334. (Pubitemid 38269584)
227. Burrell JR, Hodges JR (2010) From FUSto Fibs: what's new in frontotemporal dementia? J Alzheimers Dis 21, 349-360.
228. Arai T, Mackenzie IR, Hasegawa M, Nonoka T, Niizato K, Tsuchiya K, Iritani S, Onaya M, Akiyama H (2009) Phos-phorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol 117, 125-136.
229. Jellinger KA (2008) Neuropathological aspects of Alzheimer disease, Parkinson disease and frontotemporal dementia. Neurodegener Dis 5, 118-121. (Pubitemid 351347827)
230. Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K (2009) Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology 29, 566-573.
231. Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, Arnold SE, Siderowf A, Grossman M, Lev-erenz JB, Woltjer R, Lopez OL, Hamilton R, Tsuang DW, Galasko D, Masliah E, Kaye J, Clark CM, Montine TJ, Lee VM, Trojanowski JQ (2007) Co-morbidity of TDP-43 pro-teinopathy in Lewy body related diseases. Acta Neuropathol 114, 221-229. (Pubitemid 47226148)
232. Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, Kosaka K, Arai H (2007) Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res 1184, 284-294. (Pubitemid 350160566)
233. Kenyon C (2005) The plasticity ofaging: insights from long-lived mutants. Cell 120, 449-460. (Pubitemid 40269760)
234. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, Odijk H, Oostendorp R, Ahmad A, van Leeuwen W, Theil AF, Vermeulen W, van der Horst GT, Meinecke P, Kleijer WJ, Vijg J, Jaspers NG, Hoeijmakers JH (2006) A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444, 1038-1043. (Pubitemid 46018517)
235. Kregel KC, Zhang HJ (2007) An integrated view of oxida-tive stress in aging: basic mechanisms, functional effects, and pathological considerations. Am J Physiol Regul Integr Comp Physiol 292, R18-R36. (Pubitemid 46091599)
236. Bandyopadhyay U, Cuervo AM (2007) Chaperone-medi-ated autophagy in aging and neurodegeneration: Lessons from alpha-synuclein. Exp Gerontol 42, 120-128. (Pubitemid 44937825)
237. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006) Opposing activities protect against age-onset pro-teotoxicity. Science 313, 1604-1610. (Pubitemid 44414028)
238. Corder EH, Lannfelt L, Viitanen M, Corder LS, Manton KG, Winblad B, Basun H (1996) Apolipoprotein Egenotype determines survival in the oldest old (85 years or older) who have good cognition. Arch Neurol 53, 418-422. (Pubitemid 26143640)
239. Christensen K, Johnson TE, Vaupel JW (2006) The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet 7, 436-448. (Pubitemid 43780487)
240. Valenzuela MJ, Breakspear M, Sachdev P (2007) Complex mental activity and the aging brain: molecular, cellular and cortical network mechanisms. Brain Res Rev 56, 198-213. (Pubitemid 350103809)
241. Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M (2010) The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 6, 202-211, e207.
242. Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented byamyloid-beta immunotherapy?Nat Rev Neurol 6, 108-119.
243. Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.Curr Alzheimer Res 6, 446-450.
244. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857-868. (Pubitemid 40805347)
245. Schneider A, Mandelkow E (2008) Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics 5, 443-457. (Pubitemid 351952490)
246. Hashimoto M, Rockenstein E, Mante M, Crews L, Bar-On P, Gage FH, Marr R, Masliah E (2004) An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model. Gene Ther 11, 1713-1723. (Pubitemid 39591766)
247. Mrak RE, Griffin WS (2007) Common inflammatory mechanisms in Lewy body disease and Alzheimer disease. J Neuropathol Exp Neurol 66, 683-686. (Pubitemid 47344247)
248. Skaper SD (2007) The brain as a target for inflammatory processes and neuroprotective strategies. Ann N Y Acad Sci 1122, 23-34. (Pubitemid 350249539)
249. Sutherland GT, Sidhu KS (2011) Pluripotent stem cells for (neurodegenerative) disease modelling. In Frontiers in Pluripotent Stem Cells Research and Therapeutic Potentials; Bench-to-Bedside, Sidhu KS, ed. Bentham Press.
250. Brice A (2010) Learning from genetic forms of neurodegen-eration. Nat Med 16, 1371.
251. Barabasi AL, Gulbahce N, Loscalzo J (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12, 56-68.
252. Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A (2003) Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. J Neurol Neurosurg Psychiatry 74, 857-862. (Pubitemid 36782983)
253. Gauthier E, Fortier I, Courchesne F, Pepin P, Mortimer J, Gauvreau D (2001) Environmental pesticide exposure as a risk factor for Alzheimer's disease: a case-control study. Environ Res 86, 37-45. (Pubitemid 32473135)
254. Hubble JP, Kurth JH, Glatt SL, Kurth MC, Schellenberg GD, Hassanein RE, Lieberman A, Koller WC (1998) Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementia. Neuroepidemiology 17, 96-104. (Pubitemid 28179561)
255. Olichney JM, Murphy C, Hofstetter CR, Foster K, Hansen LA, Thal LJ, Katzman R (2005) Anosmia is very common in the Lewy body variant of Alzheimer's disease. J Neurol Neurosurg Psychiatry 76, 1342-1347. (Pubitemid 41360968)
256. Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Con-neally PM, Foroud T, Nichols WC (2006) Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 21, 45-49. (Pubitemid 43273748)
257. Barranco Quintana JL, Allam MF, Serrano Del Castillo A, Fernandez-Crehuet Navajas R (2007) Alzheimer's disease and coffee: a quantitative review. Neurol Res 29, 91-95. (Pubitemid 46185076)
258. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ (2001) Clinical and pathological diagno sis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 58, 1803-1809. (Pubitemid 33044246)
259. Snowden JS, Neary D, Mann DM (2002) Frontotemporal dementia. Br J Psychiatry 180, 140-143. (Pubitemid 34142785)
260. Woodruff BK, Graff-Radford NR, Ferman TJ, Dickson DW, De Lucia MW, Crook JE, Arvanitakis Z, Brassler S, Waters C, Barker W, Duara R (2006) Family history of dementia is a risk factor for Lewy body disease. Neurology 66, 1949-1950. (Pubitemid 44049839)
261. Sellbach AN, Boyle RS, Silburn PA, Mellick GD (2006) Parkinson's disease and family history. Parkinsonism Relat Disord 12, 399-409. (Pubitemid 44430174)
262. Hellman NE, Grant EA, Goate AM (1998) Failure to replicate a protective effect of allele 2 of NACP/alpha-synuclein polymorphism in Alzheimer's disease: an association study. Ann Neurol 44, 278-281. (Pubitemid 28374121)
263. Xia Y, Rohan de Silva HA, Rosi BL, Yamaoka LH, Rimm-ler JB, Pericak-Vance MA, Roses AD, Chen X, Masliah E, De Teresa R, Iwai A, Sundsmo M, Thomas RG, Hof- stetter CR, Gregory E, Hansen LA, Katzman R, Thal LJ, Saitoh T (1996) Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. Ann Neurol 40, 207-215. (Pubitemid 26274556)
264. Siddons MA, Pickering-Brown SM, Mann DM, Owen F, Cooper PN (1996) Debrisoquine hydroxylase gene polymorphism frequencies in patients with amyotrophic lateral sclerosis. Neurosci Lett 208, 65-68. (Pubitemid 26128109)
265. Huckvale C, Richardson AM, Mann DM, Pickering-Brown SM (2003) Debrisoquine hydroxylase gene polymorphism (CYP2D6*4) in dementia with Lewy bodies. J Neurol Neu-rosurg Psychiatry 74, 135-136. (Pubitemid 36069056)
266. Golab-Janowska M, Honczarenko K, Gawronska-Szklarz B, Potemkowski A (2007) CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia. Neurol Neurochir Pol 41, 113-121. (Pubitemid 46745847)
267. Lane R, He Y, Morris C, Leverenz JB, Emre M, Ballard C (2009) Bu Ch E-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Mov Disord 24, 392-400.